Westport, Connecticut

BioSig Awarded CAGE Code by the Systems for Award Management (SAM)

Monday, August 3, 2020 - 7:00pm

The CAGE code is required to do business operations with the federal government.

Key Points: 
  • The CAGE code is required to do business operations with the federal government.
  • The CAGE code also includes the ability to apply and be awarded government contracts, assistance and grant programs.
  • Both current and potential government vendors are required to register in SAM in order to be awarded contracts by the government.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133

Ciner Resources to Exit ANSAC on December 31, 2020

Friday, July 31, 2020 - 10:26pm

American Natural Soda Ash Corp. (ANSAC) and Ciner Resources Corporation (Ciner Resources) have reached an agreement for Ciner Resources to exit ANSAC effective December 31, 2020, one year earlier than previously announced.

Key Points: 
  • American Natural Soda Ash Corp. (ANSAC) and Ciner Resources Corporation (Ciner Resources) have reached an agreement for Ciner Resources to exit ANSAC effective December 31, 2020, one year earlier than previously announced.
  • Until the exit date, Ciner Resources will continue to meet its ANSAC membership obligations, which include utilizing ANSAC as Ciner Resources exclusive export sales outlet for U.S.-produced soda ash destined for territories served by ANSAC.
  • Following its exit from ANSAC, Ciner Resources will assume direct responsibility for its export sales and related marketing and logistics requirements that are currently being provided by ANSAC.
  • However, ANSAC has agreed to purchase a limited amount of volume from, and to provide certain logistics services to, Ciner Resources for a limited period after Ciner Resources exit.

BioSig Technologies to Participate in LD Micro’s Zooming with LD

Thursday, July 23, 2020 - 1:30pm

Despite the challenging environment, we remained steadfast in securing hospital support for the PURE EP(tm) Systems ongoing and future installations.

Key Points: 
  • Despite the challenging environment, we remained steadfast in securing hospital support for the PURE EP(tm) Systems ongoing and future installations.
  • We are pleased to reconnect with the LD Micro investor community and look forward to reporting on our progress, commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
  • BioSig Technologies, Inc.s (BSGM) subsidiary, ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133

David Kelly Returns to Westport Properties, Inc. as Vice President of Development

Wednesday, July 22, 2020 - 5:00pm

IRVINE, Calif., July 22, 2020 /PRNewswire-PRWeb/ -- Westport Properties, Inc. is excited to announce the return of David Kelly as Vice President of Development.

Key Points: 
  • IRVINE, Calif., July 22, 2020 /PRNewswire-PRWeb/ -- Westport Properties, Inc. is excited to announce the return of David Kelly as Vice President of Development.
  • Kelly previously worked as the Director of Development for five years with the company.
  • "We're thrilled to have David with the Westport Properties family again," said Charles Byerly, President and CEO of Westport Properties and US Storage Centers ("Westport").
  • David Kelly boasts several years of development and construction experience gained at Regency Centers, Snyder Langston, and Standard Pacific Homes.

Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites

Monday, July 13, 2020 - 6:42pm

The trial sites are located in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ.

Key Points: 
  • The trial sites are located in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ.
  • "Three of our four trial sites where our partners are enrolling patients are in the recognized hot spots of Texas, Arizona, and Florida.
  • We would like to thank our clinical partners for the steady progress with the trial and expect to report the trial data later this summer".
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133

BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors

Wednesday, July 1, 2020 - 2:15pm

Mr. Zook brings to the Company a wealth of commercialization experience in the life science industry gained primarily through his career at AstraZeneca Plc [LON:AZN].

Key Points: 
  • Mr. Zook brings to the Company a wealth of commercialization experience in the life science industry gained primarily through his career at AstraZeneca Plc [LON:AZN].
  • Along with the CEO, CFO, and Head of R&D, Mr. Zook sat on the Portfolio Investment Board (PIB), which set and approved the overall strategy for Research and Development and allocated resources by therapeutic area.
  • Im pleased to provide my executive and operating expertise to support the Companys goals and objectives, commented Mr. Zook.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133

BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering

Monday, June 29, 2020 - 1:18pm

The gross proceeds to the Company from this offering were $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds to the Company from this offering were $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from this offering to support commercialization, for working capital and general corporate purposes.
  • The shares of common stock were offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133

BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering

Wednesday, June 24, 2020 - 2:20pm

The gross proceeds to the Company from this offering are expected to be $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company.

Key Points: 
  • The gross proceeds to the Company from this offering are expected to be $17.5 million, before deducting placement agent fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from this offering to support commercialization and for working capital and general corporate purposes.
  • The shares of common stock are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133

Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19

Monday, June 8, 2020 - 8:02pm

The format will be a management presentation updating recent developments followed by a Q&A session with select call attendees.

Key Points: 
  • The format will be a management presentation updating recent developments followed by a Q&A session with select call attendees.
  • The article cites that merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing.
  • On May 18, 2020, ViralClear announced the FDAs clearance of its IND to proceed with a proposed Phase II study of merimepodib in COVID-19 patients.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133

ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19

Friday, June 5, 2020 - 2:10pm

The hospital is part of St. Davids HealthCare, one of the largest healthcare systems in Texas.

Key Points: 
  • The hospital is part of St. Davids HealthCare, one of the largest healthcare systems in Texas.
  • The Company intends to commence its Phase II clinical trial for merimepodib, its broad-spectrum oral anti-viral candidate for the treatment of COVID-19 in adult patients in the coming weeks.
  • Investors and security holders are urged to read these documents free of charge on the SECs website at http://www.sec.gov.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133